An observational study in Coronary Artery Disease, Antiplatelet Therapy and Minimally Invasive Coronary Revascularization Surgery, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Cardiocentro Ticino · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 47th largest by planned enrollment of the 52 observational ones that give a count, is one of 6 that started in 2024, is one of 52 observational ones, reaches primary completion later than 21 of the 40 other live ones, and was the 173rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:
B. Braun Melsungen AG · Sites in Switzerland, Germany
Ages 18+
IGLESIAS Juan Fernando · Sites in Switzerland
Ages 18+
Translumina GmbH · Sites in Switzerland
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 17 · Phase 4 25
First in 2002; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 296 across the 125 interventional studies, 992 across the 52 observational. Of the 114 that completed or were terminated, 25 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 177 have an industry lead sponsor. The 10 most frequent:
Cardiocentro Ticino is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Cardiocentro Ticino has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Coronary Artery Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04988685Luzerner KantonsspitalSIROOP Registry - a Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated with SIROlimus or Paclitaxel Eluting Balloon Catheters | 2026-12-31 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT06706323Roland von KänelDepressive Symptoms After Cardiac Surgery | 2027-04-01 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 177 studies in Coronary Artery Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.
The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.
Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?
Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.
This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.
Study Design Overview The MINOTAUR study is an open-label, single-center, case-control study assessing patients undergoing MIDCAB surgery under continuous cangrelor infusion at 0.75 μg/kg/min compared with historical controls who underwent the same procedure under aspirin therapy with or without prior cangrelor bridging. The study is exploratory and aims to evaluate safety, feasibility, and procedural aspects of intraoperative cangrelor use.
Prospective Arm: Study Intervention and Procedures
Cangrelor Administration: Prior oral antiplatelet therapies are discontinued. Cangrelor infusion is initiated based on daily platelet function testing (Multiplate®) to achieve adequate platelet inhibition before surgery.
Surgical Procedure: MIDCAB is performed ≥24 hours after cangrelor initiation, with intraoperative anticoagulation using unfractionated heparin monitored by activated clotting time.
Perioperative Monitoring: Includes daily assessment of platelet function, vital signs, ECG parameters, cardiac biomarkers (high-sensitivity troponin), and laboratory chemistry.
Data Collection: Procedural details, transfusion requirements, chest tube outputs, ICU stay, and other relevant perioperative variables are recorded in the study database.
Registry Procedures and Quality Assurance
Electronic Data Capture (EDC): All study data are entered into a secure, validated EDC system with role-based access control, audit trails, and SSL encryption. Retrospective alterations are logged in an audit table including time, user, and field changes.
Data Validation: The EDC system performs automated checks for completeness, range, and internal consistency. Central review and periodic cross-checks with source documents ensure data accuracy.
Source Data Verification: Selected data points are verified against medical records, electronic case report forms, operative reports, and lab results to ensure completeness and representativeness.
Data Dictionary: All variables are defined with source, coding standards (e.g., MedDRA, WHO Drug Dictionary), normal ranges, and units.
Standard Operating Procedures (SOPs): SOPs govern patient recruitment, data collection, data management, adverse event reporting, change management, and analytical procedures.
Audit and Monitoring: On-site monitoring is conducted according to a predefined plan, including verification of informed consent, study drug accountability, and completeness of data capture. Third-party auditing may be performed as required.
Sample Size Assessment: Approximately 30 prospective patients are targeted. No formal sample size calculation is required due to the exploratory nature; analyses are primarily descriptive.
Plan for Missing Data: Any missing, unavailable, or inconsistent data are flagged in the EDC and addressed according to predefined rules to avoid bias in analyses.
Safety Monitoring and Reporting
SAEs and ADRs: Only serious adverse events and adverse drug reactions are reported per local regulations; expected and anticipated events are predefined (e.g., bleeding, cardiac complications, acute kidney injury).
Follow-Up: Participants are monitored from inclusion through discharge. Ongoing SAEs are followed until resolution or stabilization.
Regulatory Reporting: Endpoint-related events are reported to the Ethics Committee/IRB and regulatory authorities according to timelines defined by local regulations (e.g., BASEC in Switzerland).
Statistical Analysis Plan
Continuous variables will be analyzed using t-tests or Mann-Whitney tests, depending on normality.
Categorical variables will be compared using Fisher's exact test. Analyses are exploratory and descriptive, comparing prospective cangrelor patients to historical controls.
No formal hypothesis testing is prespecified; data will inform future studies.
Data Handling and Archiving
Confidentiality: Patient data are stored securely, with restricted access. Archiving: The database, trial master file, and reports are retained electronically and in hard copy for ≥10 years.
Data Extraction: Interim and final analyses will use extracted datasets with full audit trail records.
Conclusion The MINOTAUR study is designed to provide technical and quality-controlled data on MIDCAB surgery under cangrelor infusion, with robust procedures for safety monitoring, data validation, and registry management. Findings will inform the feasibility and safety of perioperative intravenous P2Y12 inhibition for minimally invasive coronary bypass procedures.
The study population includes adult patients scheduled for minimally invasive direct coronary artery bypass (MIDCAB) surgery at Cardiocentro Ticino Institute, Lugano, Switzerland. Patients will be selected for either prospective cangrelor-guided MIDCAB or retrospective historical control MIDCAB under aspirin therapy. The population includes individuals with multivessel coronary artery disease requiring LIMA-LAD bypass, regardless of sex or comorbidities, who meet all inclusion and no exclusion criteria. Patients with planned concomitant PCI are excluded. This population represents real-world candidates for MIDCAB surgery under antiplatelet management protocols.
Inclusion Criteria for the historical control arm:
Inclusion criteria for the prospective arm:
Exclusion criteria for the historical control arm
Exclusion criteria for the prospective arm
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients prospectively enrolled to undergo MIDCAB surgery while receiving continuous cangrelor infusion at 0.75 μg/kg per minute. All prior oral antiplatelet therapy is discontinued, and platelet function is monitored daily with Multiplate® testing. Data collected include perioperative safety, bleeding outcomes, laboratory values, and clinical events.
Procedure: Cangrelor-guided MIDCAB surgery (for the prospective cases)
Retrospective patients who previously underwent MIDCAB surgery under aspirin therapy, with or without prior bridging with cangrelor. Relevant perioperative and clinical data are extracted from the institutional database for comparison with the prospective cases.
Procedure: Aspirin MIDCAB surgery (for the historical controls)
Cangrelor-guided MIDCAB surgery: Patients undergo minimally invasive direct coronary artery bypass (MIDCAB) with continuous intravenous cangrelor infusion at 0.75 μg/kg per minute. Prior oral antiplatelet therapy is discontinued, and platelet function is monitored daily using Multiplate® testing. Cangrelor infusion is started when platelet aggregation reaches predefined thresholds and continued throughout surgery until it is safe to restart oral antiplatelet therapy.
Aspirin MIDCAB surgery: Historical control patients underwent MIDCAB under aspirin therapy, with or without prior bridging with cangrelor. Perioperative management follows standard care, including anticoagulation with unfractionated heparin during surgery and routine monitoring of laboratory and clinical outcomes.
Excessive CABG-related bleeding during and after MIDCAB surgery
Excessive bleeding is defined as the occurrence of at least one of the following: (1) bleeding requiring surgical re-exploration, (2) 24-hour chest tube output greater than 1 liter, or (3) transfusion of more than 4 units of packed red blood cells. This measure assesses the safety of cangrelor-guided MIDCAB compared with historical aspirin-treated controls.
Time frame: From the start of surgery through 24 hours postoperatively
In-hospital MACCE
Occurrence of all-cause death, myocardial infarction, stroke, or urgent revascularization; each component assessed separately.
Time frame: From surgery through hospital discharge, an average of 8 days
Probable or Defined Stent Thrombosis
Incidence of stent thrombosis confirmed by angiography or clinical criteria (probable or definite).
Time frame: From surgery through hospital discharge, an average of 8 days
Cardiac Injury (High-Sensitivity Troponin)
Daily measurement of high-sensitivity troponin before and after MIDCAB to assess perioperative myocardial injury.
Time frame: Preoperative baseline until hospital discharge, an average of 10 days
Chest Tube Output
Volume of postoperative chest drainage measured at 6, 12, 24, and 48 hours after surgery.
Time frame: 6, 12, 24, and 48 hours postoperatively
Blood Transfusion Requirements and Nadir Hemoglobin
Number of packed red blood cell units transfused and lowest hemoglobin level recorded, corrected for transfusions.
Time frame: From surgery through hospital discharge, an average of 8 days
ICU Length of Stay and Mechanical Ventilation Duration
Duration of stay in intensive care and total hours of mechanical ventilation postoperatively.
Time frame: From ICU admission post-surgery to ICU discharge, an average of 12-24 hours
BARC-4 Bleeding and Universal Definition of Perioperative Bleeding
Bleeding severity assessed using BARC-4 criteria and the Universal Definition for Perioperative Bleeding (UDPB).
Time frame: From surgery through hospital discharge, an average of 8 days
Acute Kidney Injury and Renal Replacement Therapy
Incidence of acute kidney injury (creatinine increase ≥0.3 mg/dl or ≥1.5x baseline, or urine output \<0.5 ml/kg/h for ≥6h) and need for renal replacement therapy.
Time frame: From surgery through hospital discharge, an average of 8 days
Length of Hospital Stay
Total duration of hospitalization from surgery to discharge.
Time frame: From Surgery to hospital discharge, an average of 10 days
Platelet Function Under Cangrelor Infusion
Daily platelet function testing (Multiplate®) measuring ADP and arachidonic acid pathways during cangrelor infusion.
Time frame: From initiation of cangrelor infusion until hospital discharge, an average of 10 days
Vital Signs and 12-lead ECG Parameters
Monitoring of heart rate (HR, bpm), blood pressure (mmHg), and ECG parameters (PR, QRS, QTc in ms) during hospital stay.
Time frame: From surgery through hospital discharge, an average of 8 days
Standard Hematology and Blood Chemistry
Routine hematology assessments including complete blood count (CBC) parameters (e.g., hemoglobin \[g/dL\], hematocrit \[%\], white blood cell count \[×10⁹/L\], platelet count \[×10⁹/L\]). Routine blood chemistry assessments including electrolytes (e.g., sodium \[mmol/L\], potassium \[mmol/L\]), liver function tests (e.g., ALT \[U/L\], AST \[U/L\], bilirubin \[µmol/L\]), kidney function tests (e.g., creatinine \[µmol/L\], urea \[mmol/L\]), and other relevant chemistry parameters, each reported in their respective units of measure.
Time frame: Preoperative baseline through hospital discharge, an average of 10 days
Serious Adverse Events and Adverse Drug Reactions
Any untoward medical occurrence during the study that meets criteria for a Serious Adverse Event (death, life-threatening event, hospitalization, permanent impairment, or medical/surgical intervention to prevent permanent damage) or an Adverse Drug Reaction related to cangrelor infusion. Expected ADRs include bleeding, cardiac tamponade, acute kidney injury, hypersensitivity, dyspnea, or fructose intolerance. Other adverse events are monitored and recorded per protocol.
Time frame: From study inclusion through hospital discharge or resolution of ongoing events, an average of 10 days
Started May 2024 (actual). Primary completion is estimated for Jan 2028, 43 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 43 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiocentro Ticino